Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug ...

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Taiwan

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Formosa Pharmaceuticals has filed a clinical trial application for TSY-110, an antibody-drug conjugate biosimilar targeting HER2-positive breast cancers, marking a key step toward regulatory approval and commercialisation in oncology biosimilars.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup should view this as a signal that regulatory pathways for biosimilar antibodies in oncology markets like Taiwan are active and accessible. This opens a direct route to competing on price and innovation against established HER2 therapies this year.

◆ Coverage

1 source · 28 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialsbiosimilarsoncologyregulatory-filingher2-positive